Trials / Completed
CompletedNCT02101593
Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
A Phase 1 Study of ADI PEG 20 Plus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Polaris Group · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Assessment of safety and tolerability of ADI-PEG 20 in combination with sorafenib in advanced Hepatocellular Carcinoma (HCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADI-PEG 20 |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2016-02-01
- Completion
- 2016-03-01
- First posted
- 2014-04-02
- Last updated
- 2016-03-04
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02101593. Inclusion in this directory is not an endorsement.